The Journal of Urology
Volume 179, Issue 1 , Pages 28-33 , January 2008

The Will Rogers Phenomenon in Urological Oncology

  • Ofer N. Gofrit

      Affiliations

    • Corresponding Author InformationCorrespondence: Department of Surgery, Section of Urology, The University of Chicago Hospitals, 5841 South Maryland Ave.-MC6038, Chicago, Illinois 60637 (telephone: 773-702-4807; FAX: 773-702-1001).
    • ,
  • Kevin C. Zorn
    • ,
  • Gary D. Steinberg

      Affiliations

    • Financial interest and/or other relationship with Vysis, Bayer and Adolor/GSK.
    • ,
  • Gregory P. Zagaja

      Affiliations

    • Financial interest and/or other relationship with Intuitive.
    • ,
  • Arieh L. Shalhav

      Affiliations

    • Financial interest and/or other relationship with Misonix/Focus Surgery.

Received 16 February 2007

References 

  1. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon (Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer). N Engl J Med. 1985;312:1604
  2. Spratt JS. Will Rogers phenomenon. Arch Surg. 1992;127:868
  3. Bodner EB. Will Rogers and gastric carcinoma. Arch Surg. 1988;123:1023
  4. Woodward WA, Strom EA, Tucker SL, McNeese MD, Perkins GH, Schechter R, et al. Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival. J Clin Oncol. 2003;21:3244
  5. Champion GA, Piccirillo JF. The impact of computed tomography on pretherapeutic staging in patients with laryngeal cancer: demonstration of the Will Rogers’ phenomenon. Head Neck. 2004;26:972
  6. George S, Primrose J, Talbot R, Smith J, Mullee M, Bailey D, et al. Will Rogers revisited: prospective observational study of survival of 3592 patients with colorectal cancer according to number of nodes examined by pathologists. Br J Cancer. 2006;95:841
  7. Albertsen PC, Hanley JA, Barrows GH, Penson DF, Kowalczyk PD, Sanders MM, et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst. 2005;97:1248
  8. Thompson IM, Canby-Hagino E, Lucia MS. Stage migration and grade inflation in prostate cancer: Will Rogers meets Garrison Keillor. J Natl Cancer Inst. 2005;97:1236
  9. Wishnow KI, Tenney DM. Will Rogers and the results of radical cystectomy for invasive bladder cancer. Urol Clin North Am. 1991;18:529
  10. Chism DB, Hanlon AL, Troncoso P, Al-Saleem T, Horwitz EM, Pollack A. The Gleason score shift: score four and seven years ago. Int J Radiat Oncol Biol Phys. 2003;56:1241
  11. Kane CJ, Presti JC, Amling CL, Aronson WJ, Terris MK, Freedland SJ, et al. Changing nature of high risk patients undergoing radical prostatectomy. J Urol. 2007;177:113
  12. Srigley JR, Amin MB, Bostwick DG, Grignon DJ, Hammond ME. Updated protocol for the examination of specimens from patients with carcinomas of the prostate gland: a basis for checklists (Cancer Committee). Arch Pathol Lab Med. 2000;124:1034
  13. Steinberg DM, Sauvageot J, Piantadosi S, Epstein JI. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol. 1997;21:566
  14. King CR. Patterns of prostate cancer biopsy grading: trends and clinical implications. Int J Cancer. 2000;90:305
  15. Cookson MS, Fleshner NE, Soloway SM, Fair WR. Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. J Urol. 1997;157:559
  16. Epstein JI. Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: a diagnosis that should not be made. Am J Surg Pathol. 2000;24:477
  17. Thickman D, Speers WC, Philpott PJ, Shapiro H. Effect of the number of core biopsies of the prostate on predicting Gleason score of prostate cancer. J Urol. 1996;156:110
  18. Fleshner NE, Cookson MS, Soloway SM, Fair WR. Repeat transrectal ultrasound-guided prostate biopsy: a strategy to improve the reliability of needle biopsy grading in patients with well-differentiated prostate cancer. Urology. 1998;52:659
  19. Ghani KR, Grigor K, Tulloch DN, Bollina PR, McNeill SA. Trends in reporting Gleason score 1991 to 2001: changes in the pathologist’s practice. Eur Urol. 2005;47:196
  20. D’Amico AV, Chen MH, Oh-Ung J, Renshaw AA, Cote K, Loffredo M, et al. Changing prostate-specific antigen outcome after surgery or radiotherapy for localized prostate cancer during the prostate-specific antigen era. Int J Radiat Oncol Biol Phys. 2002;54:436
  21. Kupelian PA, Buchsbaum JC, Elshaikh MA, Reddy CA, Klein EA. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome. Int J Radiat Oncol Biol Phys. 2003;57:629
  22. Joslyn SA, Konety BR. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology. 2006;68:121
  23. van der Werf-Messing BH, Friedell GH, Menon RS, Hop WC, Wassif SB. Carcinoma of the urinary bladder T3NxMo treated by preoperative irradiation followed by simple cystectomy. Int J Radiat Oncol Biol Phys. 1982;8:1849
  24. Slack NH, Bross ID, Prout GR. Five-year follow-up results of a collaborative study of therapies for carcinoma of the bladder. J Surg Oncol. 1977;9:393
  25. Scanlon PW, Scott M, Segura JW. A comparison of short-course, low-dose and long-course, high-dose preoperative radiation for carcinoma of the bladder. Cancer. 1983;52:1153
  26. Bloom HJ, Hendry WF, Wallace DM, Skeet RG. Treatment of T3 bladder cancer: controlled trial of pre-operative radiotherapy and radical cystectomy versus radical radiotherapy. Br J Urol. 1982;54:136
  27. Parsons JT, Million RR. Planned preoperative irradiation in the management of clinical stage B2-C (T3) bladder carcinoma. Int J Radiat Oncol Biol Phys. 1988;14:797
  28. Koppie TM, Vickers AJ, Vora K, Dalbagni G, Bochner BH. Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed?. Cancer. 2006;107:2368
  29. Herr HW, Bochner BH, Dalbagni G, Donat SM, Reuter VE, Bajorin DF. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol. 2002;167:1295
  30. Konety BR, Joslyn SA, O’Donnell MA. Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program data base. J Urol. 2003;169:946
  31. Martinez-Pineiro JA, Gamallo C, Isorna S, Marron C, Ortas J, Contreras F. Significance and prognostic value of morphology of regional lymph nodes and of peritumoral lymphocyte infiltration in bladder cancer. Eur Urol. 1979;5:7
  32. Reyes E, Carballido J, Prieto A, Molto L, Manzano L, Alvarez-Mon M. lymphocytes infiltrating the bladder wall of patients with carcinoma of urinary bladder are in vivo activated. Eur Urol. 1997;31:472
  33. Paik ML, Scolieri MJ, Brown SL, Spirnak JP, Resnick MI. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J Urol. 2000;163:1693
  34. Gofrit ON, Mishani E, Orevi M, Klein M, Freedman N, Pode D, et al. Contribution of 11C-choline positron emission tomography/computerized tomography to preoperative staging of advanced transitional cell carcinoma. J Urol. 2006;176:940
  35. Nguyen MM, Gill IS, Ellison LM. The evolving presentation of renal carcinoma in the United States: trends from the Surveillance, Epidemiology, and End Results program. J Urol. 2006;176:2397

PII: S0022-5347(07)02291-4

doi: 10.1016/j.juro.2007.08.125

The Journal of Urology
Volume 179, Issue 1 , Pages 28-33 , January 2008

Article Tools

* Image Usage & Resolution